Current overview on the hepatitis D in Georgia

VIRAL HEPATITIS PREVENTION BOARD
TECHNICAL MEETING
The changing context of Hepatitis Delta
28-29 October 2021

Dr. Mamuka Zakalashvili
Consultant Hepatologist
Medical Center Mrcheveli, Tbilisi, Georgia
Georgia

• Georgia is located at the crossroads of Western Asia and Eastern Europe, it is bounded to the West by the Black Sea, to the North by Russia, to the South by Turkey and Armenia, and to the Southeast by Azerbaijan.

• Georgia is a lower-middle-income country
• Population is about 3.7 million
HBV in Georgia

• 2003 – HBsAg+ among pregnant women 3.1% (7/223)
  
  D. Metreveli et al. World Congress of Pathology and Laboratory Medicine, Istanbul, Turkey, 2005
  Poster 3-198.

• 2006 – estimated HBsAg+ prevalence among general population 5-7%
  

• 2012 – HBsAg+ 2% and Anti-HBc+ 29% - among healthcare workers
  
  M. Butsashvili et al., Occupational Medicine, Volume 62, Issue 8, Pages 620–626

• 2013 – HBsAg+ among pregnant women – 2.5%
  
  NCDC. statistical yearbook, 2014
In 2018, 30 EU/EEA Member States reported 24,588 cases of HBV infection, corresponding to a crude rate of 6 cases per 100,000 population.
National seroprevalence survey (2015)

• Cross-sectional, nationwide survey for hepatitis B and hepatitis C prevalence among the general population in Georgia

• Samples were chosen using a stratified, multi-stage cluster design with random sampling

• Sample: 7,000 adults, >18 years of age (born before 1998)

Kasradze A et al, Public Health. 2020;185:341-347
National seroprevalence survey (2015)

Results

<table>
<thead>
<tr>
<th>Overall</th>
<th>%</th>
<th>n</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-HBc+</td>
<td>25.9</td>
<td>1634</td>
<td>24.2 - 27.6</td>
</tr>
<tr>
<td>HBsAg+</td>
<td>2.9</td>
<td>188</td>
<td>2.4 - 3.5</td>
</tr>
</tbody>
</table>

Kasradze A et al, Public Health. 2020;185:341-347
National seroprevalence survey (2015)

Results:

HBV genotypes (n=77)

- Genotype A: 36.4%
- Genotype D: 63.6%

Co-infection:

- HBsAg+ / anti-HCV+: 13.3%
- HBsAg+ / HCV-RNA+: 7.5%

Among HBsAg-positive persons, 0.9% (95% CI = 0.0-2.0) were positive for HDV RNA (n = 4/175 [2.3%] of samples tested).

All HDV specimens were genotype 1

Kasradze A et al, Public Health. 2020;185:341-347
### National seroprevalence survey (2015)

**Results:**

#### Associated risk factors

<table>
<thead>
<tr>
<th>Characteristic (anti-HBc+)</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ever injecting drugs</td>
<td>2.46</td>
<td>1.64 - 3.69</td>
</tr>
<tr>
<td>Ever having a blood transfusion</td>
<td>1.67</td>
<td>1.32 - 2.11</td>
</tr>
<tr>
<td>Ever having sex with a commercial sex worker</td>
<td>1.46</td>
<td>1.07 - 2.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Characteristic (HBsAg)</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ever having a blood transfusion</td>
<td>2.72</td>
<td>1.54 - 4.80</td>
</tr>
<tr>
<td>Incarceration</td>
<td>2.72</td>
<td>1.25 - 5.93</td>
</tr>
</tbody>
</table>

*Ever injecting drugs was not associated with being HBsAg positive.*

Kasradze A et al, Public Health. 2020;185:341-347
National seroprevalence survey (2015) Results:

HBV knowledge

- Only 36.7% has ever heard of HBV

- Transmission:
  - Blood 23.3%
  - Sharing needles or syringes 20.6%
  - Sharing household objects like razors 18.7%

- Out of those who had heard of HBV
  - 42.8% were aware that it can be treated
  - 42.5% knew that it could be asymptomatic

- Overall, 1.1% of the surveyed population reported ever having been vaccinated against hepatitis B.

*limitation: It’s only based on Self-reporting

Kasradze A et al, Public Health. 2020;185:341-347
Hepatitis Delta Infection in Georgia
Our Experience
Data were extracted from 755 HBsAg positive patient’s medical records. HDV tests were available for 695 patients.

From total 45 Anti-HDV+ person:
- Male: N=37, 82%
- Female: N=8, 18%

Data from Mrcheveli Medical Center (05.2012-12.2019)
Data from Mrcheveli Medical Center (05.2012-12.2019)

HDV-RNA+ (n=41)

- **ACLD**
  - N=32, 78%
  - N=9, 22%

ACLD – Advanced chronic liver disease
Data from Mrcheveli Medical Center (05.2012-12.2019)

- All patients were treated with PegIFN, different duration (none of them more than 48 weeks)
- Most patients were untreated, because of the contraindication for treatment (disease severity), treatment cost, or due to mild diseases
Achievements in HBV/HDV in Georgia

1997 – screening of blood and blood products for viral hepatitis
2003 – routine HBV immunization of newborns
2008 – universal HBV screening of pregnant women
2015 – HBV screening and vaccination of all HCV infected persons within the national HCV Elimination program
2016 – mandatory HBV screening for all hospitalized patients
2019 – HBV screening and vaccination of health care workers

During this period every aspects of viral hepatitis care has been gradually improving in the country:
The coverage of HBV screening and vaccination; the knowledge and practices of the doctors; available antivirals; diagnostic tools and their quality
Key challenges in HBV/HDV care

- Insufficient infection control still remains a risk factor of HBV/HDV transmission within healthcare/non-healthcare facilities
- Low awareness about HBV/HDV infection not only in patients but also among healthcare workers
  - Very low rate of HBV vaccination among adults (born before 2003)
- Lack of standardized international HDV management guidelines
  - and even non-compliance to the HBV guidelines by the specialists
- Lack of affordability to the new HDV medications
  - The patients can’t afford to buy or to enter into the clinical trials
- There is no financial support neither from national nor from privat insurances at any level of chronic HBV/HDV management – diagnostics, surveillance or antiviral treatment
Acknowledgment

• National Center of Disease Control (NCDC), Georgia
• Center of Disease Control (CDC), United States

• Personal thanks to:
  • Paige A Armstrong
  • Irina Tskhomelidze
  • Tatia Kuchuloria
  • Shaun Shadaker
  • Ana Kasradze

Mrcheveli Team:
  • David Metreveli
  • Jaba Zarkua
  • Irakli Rtskhiladze
  • Nikoloz Abramishvili
  • and many others
Thank you for your attention!